12 research outputs found

    PHYTOSOMES ENHANCED THE ANTIBACTERIAL AND ANTIFUNGAL PROPERTIES OF LANTANA CAMARA

    Get PDF
    Aim: The aim of the work was to formulate Lantana camara phytosomes to improve the antimicrobial properties. Methods: L. camara phytosomes were prepared by solvent evaporation using soy lecithin (Phospholipon® 90H). The effect of surfactant Poloxamer 188 was carried out. The qualitative and quantitative analysis of the phytoconstituents was analyzed. The encapsulation efficiency and loading capacity were studied. Furthermore, the in vitro release profile was studied in ethanolic buffer. The inhibition zone diameter (IZD) was evaluated against three bacterial and two fungi. Results: The results showed that saponins were the most dominant phytochemical with about 7% on the plant leaves. The highest EE of 82.80% was obtained. In vitro release showed about 23% drug release at 60 min. The IZD results showed that L. camara had significantly higher activity against Escherichia coli and Listeria ivanovii than Staphylococcus aureus (p<0.05). The results also showed that for Candida albicans, L. camara phytosomes had significantly higher IZD than the extract (p<0.05). However, the L. camara extract and the formulations showed no activity against the Aspergillus flavus. Conclusions: Phytosomes enhanced the antimicrobial properties of L. camara and could serve as a good delivery system for this herbal drug

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome
    corecore